|
||
|
Pentz RD , Cohen CB, Wicclair M, DeVita MA, Flamm AL, Youngner SF, Hamric AB, McCabe MS, Glover J, Kittiko WJ, Kinlaw K, Keller J, Asch A, Kavanagh JJ, Arap A. Ethics guidelines for research with the recently dead. Nature Medicine. 2005: 11: 1145-1149. Lippman SM, Goodman PJ, Klein EA, Parnes HL, Thompson IM Jr, Kristal AR, Santella RM, Probstfield JL, Moinpour CM, Albanes D, Taylor PR, Minasian LM, Hoque A, Thomas SM, Crowley JJ, Gaziano JM, Stanford JL, Cook ED, Fleshner NE, Lieber MM, Walther PJ, Khuri FR, Karp DD, Schwartz GG, Ford LG, Coltman CA Jr. Designing the Selenium and Vitamin E Cancer Prevention Trial (SELECT). Journal of the National Cancer Institute, 97: 94-102, 2005. Seixas-Silva Jr JA, Richards TJ, Khuri FR, Wieand HS, Kim ES, Murphy B, Francisco M, Hong WK, Shin DM. Phase 2 bioadjuvant study of interferon-alpha-2a, isotretinoin, and vitamin E in locally advanced squamous cell carcinoma of the head and neck: Long term follow-up. Archives of Otolaryngology, Head and Neck Surgery, 131; 304-307, 2005. Marcus AI, Zhou J , Hamel E, Nivens M, El-Naggar A, Khuri FR, Giannakakou P. Novel target for the farnesyl transferase inhibitor, lonafarnib: increased microtubule acetylation underlies synergy with taxanes. Cancer Research, 65; 3883-3893, 2005. Papadimitrakopoulou V, Agelaki S, Tran HT, Kies M, Gagel R, Zinner R, Kim E, Ayers G, Wright J, Khuri F. Phase I study of the farnesyltransferase inhibitor BMS-214662 given weekly in patients with solid tumors. Clinical Cancer Research, 11(11) 4151-4159, 2005. Liu X, Yue P, Khuri FR, Sun SY. Decoy receptor 2 (DcR2) is a p53 target gene and regulates chemosensitivity. Cancer Research, 65(20): 9169-9175, 2005. Rogatko A, Babb JS, Tighiouart M, Khuri FR, Hudes G. New paradigm in dose-finding trials: patient-specific dosing and beyond "phase I", Clinical Cancer Research, 11(15): 5342-5346, 2005. Sun SY, Rosenberg LM, Wang X, Zhou Z, Yue P, Fu H, Khuri FR. Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition. Cancer Res, 65(16): 7052-7058, 2005. Johnson FM, Garden AS, Palmer JL, Shin DM, Morrison W, Papadimitrakopoulou V, Khuri FR, Clayman G, Goepfert H, Ang KK, Hong WK, Glisson BS. A Phase I/II Study of Neoadjuvant Chemotherapy Followed by Radiation with Boost Chemotherapy for Advanced T-stage Nasopharyngeal Carcinoma. International Journal of Radiation Oncology, Biology, Physics, 63(3): 717-724, 2005. Zhang X, Chen Z, Choe MS, Lin Y, Sun S-Y, Wieand HS, Shin HJ, Chen AY, Khuri FR, Shin DM. Tumor growth inhibition by simultaneously blocking EGFR and cyclooxygenase-2 in a xenograft model. Clinical Cancer Research, 11(17): 6261-9, 2005. Lambert, J.D., Chen, D., Wang, C.Y., Ai, N., Sang, Ho, C-T., Welsh, W.J., and Yang, C.S. Benzotropolone inhibitors of estradiol methylation: kinetics and in silico modeling studies. Bioorg. Med. Chem., 13: 2501-2507, 2005. Lambert, J.D., Rice, J.E., Hong, J., Hou, Z., and Yang, C.S. Synthesis and biological activity of the tea catechin metabolites, M4 and M6 and their methyoxy-derivatives. Bioorg. Med. Chem. Lett., 15: 873-876, 2005. Chen, D., Wang, C.Y., Lambert, J.D., Ai, N., Welsh, W.J., and Yang, C.S. Inhibition of human liver catechol-O-methytransferase by tea catechins and their metabolites: structure-activity relationship and molecular modeling studies. Biochem. Pharmacol, 69: 1523-1531, 2005. Hou, Z., Sang, S., You, H., Lee, M-J., Hong, J., Chin, K-V., and Yang, C.S. Mechanism of action of (-)-epigallocatechin-3-gallate: auto-oxidation-dependent inactivation of epidermal growth factor receptor and direct effects on growth inhibition in human esophageal cancer KYSE 150 cells, Cancer Res., 65: 8049-8056, 2005. Lambert, J.D., Hong, J., Yang, G-Y., Liao, J., and Yang, C.S. Inhibition of carcinogenesis by polyphenols: evidence from laboratory investigations. J. Am. Clin. Nutr., 81: 284S-291S, 2005. Ju, J., Hong, J., Zhou, J-N., Pan, Z., Bose, M., Liao, J., Yang, G-Y., Liu, Y.Y., Hou, Z., Lin, Y., Ma, J., Shih, W.J., Carothers, A.M., and Yang, C.S. Inhibition of intestinal tumorigenesis in Apc min/+ mice by (-)-epigallocatechin-3-gallate, the major catechins in green tea. Cancer Res. 65: 10623-10631, 2005. Sang, S., Lambert, J.D., Hong, J., Tian, S., Lee, M-J., Stark, R.E., Ho, C-T., and Yang, C.S. Synthesis and structure identification of thiol conjugates of (-)-epigallocatechin gallate and their urinary levels in mice. Chem. Res. Toxicol. 18: 1762-1769, 2005. |
|
Sang, S., Lee, M-J., Hou, Z., Ho, C-T., and Yang, C.S. Stability of (-)-epigallocatecin-3-gallate under common experimental conditions. J. Arg. Food Chem. 53: 9478-9484, 2005. Asif G., Hurwitz, S.J., Chu, C.K., McClure., M.K., & Schinazi, R.F. 2005. Pharmacokinetics of the antiviral agent β-L-3’-fluoro-2’,3’-dideoxycytid Hurwitz, S.J., Otto, M.J. & Schinazi, R.F. 2005. Comparative pharmacokinetics of Racivir®, (±)-β-2',3'-dideoxy-5-fluoro-3'- thiacytidine, in rats, rabbits, dogs, monkeys and HIV-infected humans. Antiviral Chem. Chemother. 16: 117-127. Moore, C., Hernández-Santiago, B.L., Hurwitz, S.J., Tan, C., Wang, C. & Schinazi, R.F. 2005, The boron-neutron capture agent β-D-5-o-carboranyl-2’-deoxyuridine accumulates preferentially in dividing brain tumor cells. J. Neurooncol 74:275-80. Ray, A.S., Hernandez-Santiago, B.I., Mathew, J.S., Murakami, E., Bozeman, C., Xie, M.Y., Dutschman, G.E., Gullen, E., Yang, Z., Hurwitz, S.J., Cheng, Y.C., Chu, C.K., McClure, H., Schinazi, R.F., Anderson, K.S., 2005. Mechanism of anti-human immunodeficiency virus activity of β-D-6-cyclopropylamino-2',3' Hernández-Santiago, B.L., Chen, H., Asif G., Beltran, T., Mao, S., Hurwitz, S.J., Grier, J., McClure, H.M., Chu, C.K., Liotta, D.C., & Schinazi, R.F. 2005. Pharmacology and pharmacokinetics of the antiviral agent β-D-2’,3’-dideoxy-3’-oxa-5 Sun S-Y. Chemopreventive agent-induced modulation of death receptors. Apoptosis, 10:1203-10, 2005. Gao, X., Yang, L., Petros, J. A., Marshall, F. F., Simons, J. W., and Nie, S. In vivo molecular and cellular imaging with quantum dots. Curr Opin Biotechnol, 16: 63-72, 2005. Chen, P. E., Geballe, M. T., Stansfeld, P. J., Johnston, A. R., Yuan, H., Jacob, A. L., Snyder, J. P., Traynelis, S. F., and Wyllie, D. J. Structural features of the glutamate binding site in recombinant NR1/NR2A N-methyl-D-aspartate receptors determined by site-directed mutagenesis and molecular modeling. Mol Pharmacol, 67: 1470-1484, 2005. Peng, X. H., Cao, Z. H., Xia, J. T., Carlson, G. W., Lewis, M. M., Wood, W. C., and Yang, L. Real-time detection of gene expression in cancer cells using molecular beacon imaging: new strategies for cancer research. Cancer Res, 65: 1909-1917, 2005. Yang, C. S., Liao, J., Yang, G. Y., and Lu, G. Inhibition of lung tumorigenesis by tea. Exp Lung Res, 31: 135-144, 2005. Sood, S., Shiff, S. J., Yang, C. S., and Chen, X. Selection of topically applied non-steroidal anti-inflammatory drugs for oral cancer chemoprevention. Oral Oncol, 41: 562-567, 2005. Tighiouart, M., Rogatko, A., and Babb, J. S. Flexible Bayesian methods for cancer phase I clinical trials. Dose escalation with overdose control. Stat Med, 24: 2183-2196, 2005. Marcus, A. I., Peters, U., Thomas, S. L., Garrett, S., Zelnak, A., Kapoor, T. M., and Giannakakou, P. Mitotic kinesin inhibitors induce mitotic arrest and cell death in Taxol-resistant and -sensitive cancer cells. J Biol Chem, 280: 11569-11577, 2005. Escuin, D., Kline, E. R., and Giannakakou, P. Both microtubule-stabilizing and microtubule-destabilizing drugs inhibit hypoxia-inducible factor-1alpha accumulation and activity by disrupting microtubule function. Cancer Res, 65: 9021-9028, 2005. Wang, Y., O'Brate, A., Zhou, W., and Giannakakou, P. Resistance to microtubule-stabilizing drugs involves two events: beta-tubulin mutation in one allele followed by loss of the second allele. Cell Cycle, 4: 1847-1853, 2005. Zhang, X., Chen, Z. G., Choe, M. S., Lin, Y., Sun, S. Y., Wieand, H. S., Shin, H. J., Chen, A., Khuri, F. R., and Shin, D. M. Tumor growth inhibition by simultaneously blocking epidermal growth factor receptor and cyclooxygenase-2 in a xenograft model. Clin Cancer Res, 11: 6261-6269, 2005. Choe, M. S., Zhang, X., Shin, H. J., Shin, D. M., and Chen, Z. G. Interaction between epidermal growth factor receptor- and cyclooxygenase 2-mediated pathways and its implications for the chemoprevention of head and neck cancer. Mol Cancer Ther, 4: 1448-1455, 2005. Adams, B. K., Cai, J., Armstrong, J., Herold, M., Lu, Y. J., Sun, A., Snyder, J. P., Liotta, D. C., Jones, D. P., and Shoji, M. EF24, a novel synthetic curcumin analog, induces apoptosis in cancer cells via a redox-dependent mechanism. Anticancer Drugs, 16: 263-275, 2005. Chi, A. C., Owings, J. R., Jr., and Muller, S. Peripheral odontogenic keratocyst: report of two cases and review of the literature. Oral Surg Oral Med Oral Pathol Oral Radiol Endod, 99: 71-78, 2005. Smith, W. and Saba, N. Retinoids as chemoprevention for head and neck cancer: where do we go from here? Crit Rev Oncol Hematol, 55: 143-152, 2005 .
|
||
| Last update: July 31st, 2008 by Robert Fu & Edwin Shin |
||